Document is current
Any future updates will be listed below
-
Authors
Święczkowski, Michał
Lip, Gregory Y.H.
Kurasz, Anna
Jemielita, Piotr
Duzinkiewicz, Małgorzata
Januszko, Tomasz
Dobrzycki, Sławomir
Kuźma, Łukasz
-
Funding
Funding for this research was provided by:
Medical Univeristy of Bialystok (B.SUB.25.155, B.SUB.25.560)
- License Information
-
More Information
Article History
Received: 27 March 2025
Accepted: 8 September 2025
First Online: 29 September 2025
Declarations
:
: The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the Bioethics Committee of the Medical University of Bialystok (approval number APK.002.81.2022). Patient consent was waived by the Bioethics Committee of the Medical University of Bialystok due to the use of anonymized data.
: Not applicable.
: G.Y.H.L: Consultant and speaker for BMS/Pfizer, Boehringer Ingelheim, Daiichi-Sankyo, Anthos. No fees are received personally. He is a National Institute for Health and Care Research (NIHR) Senior Investigator and co-PI of the AFFIRMO project on multimorbidity in AF (grant agreement No 899871), TARGET project on digital twins for personalised management of atrial fibrillation and stroke (grant agreement No 101136244) and ARISTOTELES project on artificial intelligence for management of chronic long term conditions (grant agreement No 101080189), which are all funded by the EU’s Horizon Europe Research & Innovation programme. Other authors declare no conflicts of interest.
